<?xml version="1.0" encoding="UTF-8"?>
<collection>
<dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:invenio="http://invenio-software.org/elements/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:identifier>doi:10.4321/S1130-01082013000100005</dc:identifier><dc:language>eng</dc:language><dc:creator>Ortiz-Lucas, M.</dc:creator><dc:creator>Tobias, A.</dc:creator><dc:creator>Saz, P.</dc:creator><dc:creator>Sebastián, J.J.</dc:creator><dc:title>Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis</dc:title><dc:identifier>ART-2013-100050</dc:identifier><dc:description>Background and objectives: immune system alteration in irritable bowel syndrome (IBS) patients may be modulated by probiotics. We assessed the efficacy of some probiotic species in alleviating characteristic IBS symptoms. Material and methods: a meta-analysis of all identified randomized controlled trials comparing probiotics with placebo in treating IBS symptoms was performed with continuous data summarized using standardized mean differences (SMDs) with 95% confidence intervals (95% CIs), where appropriate. The randomeffects model was employed in cases of heterogeneity; otherwise, fixed-effects models were used. Results: meta-analysis was performed with 10 of 24 studies identified as suitable for inclusion. Probiotics improved pain scores if they contained Bifidobacterium breve (SMD, -0.34; 95% CI, -0.66; -0.02), Bifidobacterium longum (SMD, -0.48; 95% CI, -0.91; -0.06), or Lactobacillus acidophilus (SMD, -0.31; 95% CI, -0.61; -0.01) species. Distension scores were improved by probiotics containing B. breve (SMD, -0.45; 95% CI, -0.77; -0.13), Bifidobacterium infantis, Lactobacillus casei, or Lactobacillus plantarum(SMD, -0.53; 95% CI, -1.00; -0.06) species. All probiotic species tested improved flatulence: B. breve (SMD, -0.42; 95% CI, -0.75; -0.10), B. infantis, L. casei, L. plantarum(SMD, -0.60; 95% CI, -1.07; -0.13), B. longum, L. acidophilus, Lactobacillus bulgaricus, and Streptococcus salivarius ssp. thermophilus (SMD, -0.61; 95% CI, -1.01; -0.21). There was not a clear positive effect of probiotics concerning the quality of life. Conclusions: some probiotics are an effective therapeutic option for IBS patients, and the effects on each IBS symptom are likely species-specific. Future studies must focus on the role of probiotics in modulating intestinal microbiota and the immune system while considering individual patient symptom profiles.</dc:description><dc:date>2013</dc:date><dc:source>http://zaguan.unizar.es/record/62055</dc:source><dc:doi>10.4321/S1130-01082013000100005</dc:doi><dc:identifier>http://zaguan.unizar.es/record/62055</dc:identifier><dc:identifier>oai:zaguan.unizar.es:62055</dc:identifier><dc:identifier.citation>Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva 105, 1 (2013), 19-36</dc:identifier.citation><dc:rights>by-nc</dc:rights><dc:rights>http://creativecommons.org/licenses/by-nc/3.0/es/</dc:rights><dc:rights>info:eu-repo/semantics/openAccess</dc:rights></dc:dc>

</collection>